Dr. Prashant Tembhare, is a Clinician Scientist and Professor in Department of Hematopathology, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Center, Navi Mumbai. He obtained an MD in Pathology and a Hematopathology fellowship in Tata Memorial Centre. Then he completed a post-doctoral fellowship in Flow Cytometry Laboratory, CCR-NCI, NIH, Bethesda, USA. He has been working at TMC since 2013. Presently he is a Treasurer of The Cytometry Society-India. He has published more than 100 research articles with more than 7862 citations with H-index of 27. He has written flow cytometry chapters in six international textbooks. He has received many national and international awards. He is representing India in international collaborations such as International Collaboration in Cancer Reporting (ICCR) for Multiple myeloma and ELN-DAVID for AML MRD and one of the members of ELN group for AMLMRD by spectral flow cytometry. He has authored 13 topics in the 5th WHO book for Hematolymphoid neoplasm. He is on the editorial board and reviewer for many national and international journals including Clinical Cytometry B. His expertise includes the flow cytometric assessment of high-sensitivity MRD monitoring in B-ALL, T-ALL, and Myeloma, 16-color MRD in AML, CLL and T-NHL. He also works on flow cytometric analysis in MDS, CMML, B and T-NHL, DNA ploidy evaluation and Pediatric round cell tumor determination. He has also developed 16-color deep immune cell profile monitoring, CAR-T-cell monitoring assay and antiCD19 B-ALL MRD assay. Currently he is working on 22-color AML MRD using full Spectrum flow cytometry and Ultrasensitive Blood based MRD assessment in multiple myeloma.

Dr Raslan is a faculty member from NCI, Cairo university, full Professor since 2010. She joined KFSH-Dammam, 2007 and ongoing, Consultant Hematopathology, Created and implemented the Flowcytometry section, and have been the section head up to 2022, head of hematology section from 2019-2022. Dr. Raslan holding medical doctorate degree in Hematology and Oncological Hematology, she has Excellent experience in hematological malignancies, flowcytometry and teaching. She has leadership skills involving managing, and motivating teams to achieve their objectives. Maintaining high quality standards, she holds Six Sigma and TQM, and passed through multiple auditing from JCI, CAP and CPAHI. Dr Raslan Published 30 research papers in international and national Journals, 7 accepted abstracts, and has been speaker in many conferences, workshop, and advisory consultant on MPN, myeloma and leukemia committees, she attended more than 50 conferences and workshops.

Dr. Prashant Tembhare, is a Clinician Scientist and Professor in Department of Hematopathology, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Center, Navi Mumbai. He obtained an MD in Pathology and a Hematopathology fellowship in Tata Memorial Centre. Then he completed a post-doctoral fellowship in Flow Cytometry Laboratory, CCR-NCI, NIH, Bethesda, USA. He has been working at TMC since 2013. Presently he is a Treasurer of The Cytometry Society-India. He has published more than 100 research articles with more than 7862 citations with H-index of 27. He has written flow cytometry chapters in six international textbooks. He has received many national and international awards. He is representing India in international collaborations such as International Collaboration in Cancer Reporting (ICCR) for Multiple myeloma and ELN-DAVID for AML MRD and one of the members of ELN group for AMLMRD by spectral flow cytometry. He has authored 13 topics in the 5th WHO book for Hematolymphoid neoplasm. He is on the editorial board and reviewer for many national and international journals including Clinical Cytometry B. His expertise includes the flow cytometric assessment of high-sensitivity MRD monitoring in B-ALL, T-ALL, and Myeloma, 16-color MRD in AML, CLL and T-NHL. He also works on flow cytometric analysis in MDS, CMML, B and T-NHL, DNA ploidy evaluation and Pediatric round cell tumor determination. He has also developed 16-color deep immune cell profile monitoring, CAR-T-cell monitoring assay and antiCD19 B-ALL MRD assay. Currently he is working on 22-color AML MRD using full Spectrum flow cytometry and Ultrasensitive Blood based MRD assessment in multiple myeloma.